{
  "meta": {
    "title": "Lipoproteins_And_Lipid_Storage_Disorders",
    "url": "https://brainandscalpel.vercel.app/lipoproteins-and-lipid-storage-disorders-7e532ed6.html",
    "scrapedAt": "2025-11-30T11:11:45.281Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Polar lipids and amphipathic lipids</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-polar lipids and amphipathic lipids</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Polar lipids and amphipathic lipids</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Non-polar lipids and amphipathic lipids</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Lipoproteins consist of:</span></p>",
      "unique_key": "DT1169862",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169862,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Lipoproteins consist of <strong>non-polar lipids and amphipathic lipids</strong>. Since <strong>lipids are insoluble in water</strong>, their transport in the blood is facilitated by the formation of <strong>lipoproteins</strong>, which are water-miscible.</li>\n<li>The <strong>non-polar lipids</strong>, such as <strong>triacylglycerol and cholesterol esters</strong>, are sequestered in the core of the lipoprotein.</li>\n<li>These are surrounded by <strong>amphipathic lipids</strong>, including <strong>phospholipids and cholesterol</strong>, which form a surface monolayer that makes the complex <strong>soluble in the aqueous environment</strong> of plasma.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Polar lipids and amphipathic lipids (Option A):</strong> Polar lipids are not the primary core content of lipoproteins; the core is made up of <strong>non-polar lipids</strong>.</p>\n<p><strong>Polar lipids and amphipathic lipids</strong> <strong>(Option C):</strong> The term <strong>amphiphobic lipids</strong> is not biochemically accurate; the correct term is <strong>amphipathic lipids</strong>.</p>\n<p><strong>Non-polar lipids and amphipathic lipids (Option D):</strong> Though non-polar lipids are correct, the term <strong>amphiphobic</strong> is incorrect.</p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicrons and LDL</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicrons and HDL</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicrons and VLDL</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicrons and IDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Lipoproteins mediate the transport of lipids from the intestine and liver to tissues by?</span></p>",
      "unique_key": "DT1169865",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169865,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Chylomicrons</strong> transport <strong>dietary lipids</strong> (mainly triacylglycerols) absorbed from the <strong>intestine</strong> to peripheral tissues.</li>\n<li><strong>VLDL (Very Low-Density Lipoprotein)</strong> transports <strong>endogenously synthesised lipids</strong>, mainly triacylglycerols, from the <strong>liver</strong> to peripheral tissues.</li>\n<li>These lipoproteins contain a core of <strong>non-polar lipids</strong> (triacylglycerol and cholesteryl esters) surrounded by a monolayer of <strong>amphipathic lipids</strong> (phospholipids and cholesterol) and <strong>apolipoproteins</strong>, enabling their <strong>aqueous solubility</strong> in plasma.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Chylomicrons and LDL (Option A):</strong> LDL primarily transports <strong>cholesterol</strong> to peripheral tissues, not triacylglycerols.</p>\n<p><strong>Chylomicrons and HDL (Option B):</strong> HDL mediates <strong>reverse cholesterol transport</strong> from peripheral tissues to the liver.</p>\n<p><strong>Chylomicrons and IDL (Option D):</strong> IDL is a transient product formed during VLDL degradation and is not a major transporter.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>Defects in chylomicron metabolism (e.g., <strong>Type I hyperlipoproteinemia</strong>) or VLDL metabolism (e.g., <strong>Type IIb</strong>) lead to <strong>hyperlipidemias</strong>.</li>\n<li>Measurement of lipoproteins is essential in assessing <strong>cardiovascular risk</strong>.</li>\n</ul>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo-E</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo-C</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo-A</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo-B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The apoprotein responsible for the transport of the lipoprotein from the plasma into the liver is?</span></p>",
      "unique_key": "DT1169882",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169882,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The apoprotein responsible for <strong>remnant uptake</strong> by the <strong>liver</strong> is <strong>Apo-E</strong>.</li>\n<li>It facilitates the <strong>transport of lipoproteins from the plasma into the liver</strong>.</li>\n<li>Apo-E is <strong>stored in HDL</strong> and is <strong>transferred into lipoproteins</strong> (such as chylomicron remnants and IDL) when needed.</li>\n<li>Notably, <strong>Apo-E is present on all lipoproteins except LDL</strong>.</li>\n<li><strong>Deficiency or mutations</strong> in Apo-E (e.g., <strong>ApoE2 homozygosity</strong>) can lead to <strong>familial dysbetalipoproteinemia</strong>, characterised by remnant accumulation and premature atherosclerosis.</li>\n<li>Apo-E polymorphisms (E2, E3, E4) have implications in both <strong>lipid metabolism</strong> and <strong>neurological diseases</strong> (e.g., ApoE4 in Alzheimer's).</li>\n</ul>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509013319a1ce-ffdd-40af-95ab-695f3e19a010.png\">",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatic lipase degrades TGs in IDL</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Hormone-sensitive lipase degrades TGs in adipocytes</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Lipoprotein lipase degrades TGs in circulating Chylomicrons and VLDLs in the Hepatic endothelium</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Pancreatic lipase degrades TGs in the small intestine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">False regarding the different lipases involved in lipid metabolism?</span></p>",
      "unique_key": "DT1169888",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169888,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Lipoprotein lipase degrades TGs in circulating Chylomicrons and VLDLs in the Hepatic endothelium is <strong>false</strong> because <strong>lipoprotein lipase (LPL)</strong> is located in the <strong>vascular endothelium</strong> of <strong>extrahepatic tissues</strong> such as <strong>muscle</strong> and <strong>adipose tissue</strong>, <strong>not the hepatic endothelium</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509010a180bd7-4d36-44ba-89aa-a7b901c7b96e.png\">\n<p><strong>Key takeaways:</strong></p>\n<ul>\n<li><strong>Defects in lipoprotein lipase</strong> can cause <strong>Type I hyperlipoproteinemia</strong>, leading to elevated chylomicrons and severe hypertriglyceridemia.</li>\n<li><strong>Hepatic lipase deficiency</strong> can impair the conversion of IDL to LDL and affect cholesterol transport.</li>\n<li>Pancreatic lipase insufficiency (e.g., in chronic pancreatitis) causes <strong>fat malabsorption</strong> and <strong>steatorrhea</strong>.</li>\n</ul>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">HDL is synthesised in the liver only</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo-C and Apo-E are synthesised in the liver and the intestine</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">HDL is required for the metabolism of Chylomicrons only</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Scavenger receptors are present on HDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding HDL is true?</span></p>",
      "unique_key": "DT1169900",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169900,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>HDL</strong> expresses <strong>Class B Scavenger Receptor B1 (SR-B1)</strong>.</li>\n<li>It has a <strong>dual function</strong> in HDL metabolism:\n<ol>\n<li><strong>Cholesterol Uptake</strong>: In the <strong>liver</strong> and <strong>steroidogenic tissues</strong>, SR-B1 binds HDL via <strong>Apo-A1</strong>, facilitating the delivery of cholesterol to these tissues.</li>\n<li><strong>Reverse Cholesterol Transport</strong>: SR-B1 also mediates the uptake of <strong>effluxed cholesterol</strong> from peripheral tissues into HDL, which is then transported to the liver and <strong>excreted in bile</strong>.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509019c34954c-7776-4834-90dd-a7ee430197b6.png\"></li>\n</ol>\n</li>\n</ul>\n<h3><strong>Reverse Cholesterol Transport Components:</strong></h3>\n<ul>\n<li><strong>ABCA1</strong>: Facilitates cholesterol efflux to lipid-poor Apo-A1</li>\n<li><strong>ABCG1</strong>: Transfers cholesterol to mature HDL</li>\n<li><strong>LCAT</strong>: Converts cholesterol to cholesteryl ester</li>\n<li><strong>CE</strong>: Cholesterol ester</li>\n<li><strong>PL</strong>: Phospholipid</li>\n<li><strong>Apo-A1</strong>: Key HDL apolipoprotein.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>HDL is synthesised in the liver only (Option A):</strong> HDL is synthesised <strong>in both the liver and the intestine</strong>, not the liver alone.</p>\n<p><strong>Apo-C and Apo-E are synthesised in the liver and intestine (Option B):</strong> <strong>Apo-E and Apo-C</strong> are synthesised <strong>only in the liver</strong>, not both liver and intestine.</p>\n<p><strong>HDL is required for the metabolism of Chylomicrons only (Option C):</strong> HDL is required for the metabolism of <strong>both chylomicrons and VLDL</strong>, not just chylomicrons.</p>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">When present in large quantities can cause coronary heart disease</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Has an extra apo(a) molecule attached to Apo B-48</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Lp(a) is structurally related to LDL</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Niacin reduces Lp(a)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are true regarding lipoprotein (a) except?</span></p>",
      "unique_key": "DT1169936",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169936,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Structurally</strong>,<strong> Lp(a)</strong> is <strong>nearly identical to LDL</strong>. <strong>(Option C)</strong>\n<ul>\n<li>Its distinguishing feature is the <strong>presence of an additional apolipoprotein molecule, apo(a)</strong>.</li>\n<li>This <strong>apo(a)</strong> is <strong>covalently linked</strong> at a <strong>single site</strong> to <strong>apo B-100</strong>, <strong>not Apo B-48</strong>.</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>Lipoprotein (a) [Lp(a)]</strong> is a <strong>lipoprotein particle</strong> that, when present in large amounts in the plasma, is associated with an <strong>increased risk of coronary heart disease (CHD)</strong>. <strong>(Option A)</strong></li>\n<li><strong>Genetics</strong> primarily determines circulating Lp(a) levels. However, dietary factors can have some influence:\n<ul>\n<li><strong>&uarr; Lp(a):</strong> Trans fatty acids</li>\n<li><strong>&darr; Lp(a):</strong> Omega-3 fatty acids</li>\n</ul>\n</li>\n<li><strong>Apo(a)</strong> is <strong>structurally homologous to plasminogen</strong>, the <strong>precursor of plasmin</strong>, which breaks down fibrin in clots.</li>\n<li>Therefore, elevated Lp(a) <strong>competes with plasminogen</strong>, possibly <strong>slowing fibrin breakdown</strong>, contributing to atherothrombosis.</li>\n<li><strong>The exact physiological role of Lp(a)</strong> remains <strong>unknown</strong>.</li>\n<li><strong>Niacin</strong> (vitamin B3):\n<ul>\n<li><strong>&darr; Lp(a) (Option D)</strong></li>\n<li><strong>&darr; LDL-cholesterol &amp; TAGs</strong></li>\n<li><strong>&uarr; HDL</strong></li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicron</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">VLDL</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">HDL</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The lipoprotein that moves the fastest towards the anode is?</span></p>",
      "unique_key": "DT1169938",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169938,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer </strong>:</p>\n<ul>\n<li>The placement of the lipoproteins in electrophoresis depends on the <strong>charge</strong> and <strong>mass</strong> of the lipoproteins. The <strong>higher the protein content,</strong> the <strong>faster the lipoprotein moves.</strong></li>\n<li>In this aspect, <strong>HDL</strong> travels the <strong>fastest</strong> and <strong>towards</strong> <strong>the anode,</strong> and Chylomicrons remain at the origin.</li>\n<li>Lipoprotein electrophoresis is useful in evaluating <strong>dyslipidemias</strong> and <strong>lipoprotein disorders</strong>.</li>\n</ul>\n<p>The sequence in electrophoresis is as follows:</p>\n<ul>\n<li>Chylomicrons are the <strong>largest and least dense</strong> lipoproteins with <strong>minimal protein content</strong>; thus, they migrate the <strong>slowest</strong>. <strong>(Option A ruled out)</strong></li>\n<li>VLDL has <strong>intermediate protein content</strong>, migrates more slowly than HDL but faster than chylomicrons. <strong>(Option B ruled out)</strong></li>\n<li>LDL has <strong>less protein than HDL</strong> and therefore migrates <strong>more slowly</strong>. <strong>(Option D ruled out)</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250901cf5f27ed-b8ec-4f7a-8443-56e720cf6bfc.png\">",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">RNA splicing</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">RNA editing</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">RNA silencing</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">RNA pre-translational modification</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The process of formation of Apo-B48 from Apo-B is by?</span></p>",
      "unique_key": "DT1169940",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169940,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The process of formation of <strong>Apo B-48</strong> from <strong>Apo B</strong> occurs through <strong>RNA editing</strong>.</li>\n<li>This is a <strong>post-transcriptional modification</strong> where a <strong>cytidine (C)</strong> is <strong>deaminated to uridine (U)</strong> in the <strong>mRNA</strong> of the <strong>apo B gene</strong> in <strong>intestinal cells</strong>.</li>\n<li>As a result, a <strong>premature stop codon</strong> is introduced, leading to the production of a <strong>shorter protein</strong>, <strong>Apo B-48</strong>, instead of the full-length <strong>Apo B-100</strong> (which is produced in the liver).</li>\n<li>ApoB-48 is synthesised in the <strong>intestine</strong>, whereas ApoB-100 is produced in the</li>\n<li><strong>ApoB-48 is a structural component of chylomicrons, while ApoB-100 is found in VLDL, IDL, and LDL.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>RNA splicing (Option A): </strong>RNA splicing removes introns from pre-mRNA but does <strong>not</strong> result in the formation of ApoB-48.</p>\n<p><strong>RNA silencing</strong> <strong>(Option C): </strong>RNA silencing refers to gene expression inhibition via mechanisms such as siRNA or miRNA; not relevant to ApoB processing.</p>\n<p><strong>RNA pre-translational modification</strong> <strong>(Option D): </strong>This is a vague and non-standard term; the correct mechanism is <strong>RNA editing</strong>.</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicron</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicron remnant</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">VLDL</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following is the largest lipoprotein?</span></p>",
      "unique_key": "DT1169943",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169943,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Among the lipoproteins, <strong>chylomicrons are the largest</strong>, and <strong>HDL is the smallest</strong>.</li>\n<li>Lipoproteins differ in size, density, and protein/lipid composition.</li>\n<li>The <strong>relative size order</strong> from largest to smallest is:<br /> <strong>Chylomicron &gt; Chylomicron remnant &gt; VLDL &gt; LDL &gt; HDL</strong></li>\n<li>The large size of chylomicrons correlates with their function of transporting <strong>dietary triglycerides</strong> from the intestine to peripheral tissues.</li>\n</ul>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Low LDL and low cholesterol</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">High LDL and low cholesterol</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">High  LDL and high cholesterol</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Low LDL and High cholesterol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Characteristics of Familial hyperlipoproteinemia?</span></p>",
      "unique_key": "DT1169949",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169949,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Type IIa Hyperlipoproteinemia</strong> (Familial Hypercholesterolemia) is also known as <strong>Autosomal Dominant Hypercholesterolemia</strong>.</li>\n<li>It is an <strong>autosomal dominant disorder</strong> caused by <strong>mutations in the LDL receptor gene</strong>, leading to defective or absent LDL receptors.</li>\n<li>As a result, <strong>LDL clearance is impaired</strong>, causing the <strong>accumulation of LDL in plasma</strong>.</li>\n<li><strong>Homozygotes</strong> have <strong>2 defective alleles</strong>, resulting in <strong>extremely elevated LDL and total cholesterol levels</strong>, ranging from <strong>500-1,200 mg/dL</strong>.</li>\n<li><strong>Triglyceride levels</strong>: Normal to mildly elevated</li>\n<li><strong>HDL levels</strong>: May be slightly decreased.</li>\n</ul>\n<p><strong>Genes implicated in Type IIa Familial Hypercholesterolemia:</strong></p>\n<ul>\n<li><strong>LDLR gene</strong> mutation (the most common cause)</li>\n</ul>\n<p>Other less common causes:</p>\n<ul>\n<li><strong>APOB gene</strong> <strong>(ApoB-100)</strong> mutation - affects binding to LDL receptor</li>\n<li><strong>PCSK9 gain-of-function</strong> mutation - enhances LDL receptor degradation</li>\n</ul>\n<h3><strong>Clinical Features:</strong></h3>\n<ul>\n<li><strong>Receptor-negative patients</strong>: &lt;2% normal LDL receptor activity</li>\n<li><strong>Receptor-defective patients</strong>: Up to 25% normal activity &rarr; Better prognosis</li>\n<li><strong>Presentation</strong>:\n<ul>\n<li><strong>Premature coronary artery disease (CAD)</strong></li>\n<li><strong>Corneal arcus</strong></li>\n<li><strong>Tendon xanthomas</strong> - Especially at the <strong>Achilles tendon</strong>, <strong>hands</strong>, <strong>elbows</strong>, <strong>knees</strong>, and <strong>buttocks</strong></li>\n<li><strong>Strong family history</strong> of <strong>premature CAD</strong> and <strong>sudden cardiac death.</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Complications:</strong></p>\n<ul>\n<li><strong>Premature coronary artery disease (CAD)</strong></li>\n<li><strong>Tendon xanthomas (Achilles tendon, elbows, knees)</strong></li>\n<li><strong>Corneal arcus</strong></li>\n</ul>\n<p><strong>Genetic pattern:</strong></p>\n<ul>\n<li><strong>Receptor-negative FH: &lt;2% receptor activity &rarr; severe disease</strong></li>\n<li><strong>Receptor-defective FH: 2-25% receptor activity &rarr; better prognosis<br /> </strong></li>\n</ul>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">A/K/A familial dysbetalipoproteinemia/Familial broad beta disease</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Mutation of the Apo-E gene</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicron remnant and VLDL are elevated</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is false about type 3 hyperlipoproteinemia?</span></p>",
      "unique_key": "DT1169952",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169952,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Type III Hyperlipoproteinemia</strong> is also called <strong>familial dysbetalipoproteinemia</strong>, <strong>remnant removal disease</strong>, or <strong>broad beta disease</strong>.<strong> (Option A)</strong></li>\n<li>It is caused by a <strong>mutation in the Apo-E gene</strong>, which is essential for hepatic uptake of chylomicron remnants and IDL. <strong>(Option B)</strong></li>\n<li>The mutation impairs remnant clearance, leading to the <strong>accumulation of chylomicron remnants and VLDL</strong>, resulting in <strong>mixed hyperlipidemia</strong>. <strong>(Option C)</strong></li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250901239f669c-99de-44e0-b5b4-c143b4fae29d.png\">",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">MTP-Tangier's disease</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">ABCA1 - Tangier's disease</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">MTP- abetalipoproteinemia</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">ABCA1- abetalipoproteinemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young child presents with diarrhoea, pigmentary retinopathy and bleeding manifestations. On closer examination, there is failure to thrive, blood reports show acanthocytosis and decreased LDL, VLDL and Chylomicron levels. Defect of which gene is the probable cause?</span></p>",
      "unique_key": "DT1169953",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169953,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The clinical presentation described (failure to thrive, diarrhea, pigmentary retinopathy, acanthocytosis, and reduced LDL/VLDL/chylomicrons) is classic for <strong>abetalipoproteinemia</strong>, which is due to a mutation in the <strong>microsomal triglyceride transfer protein (MTP)</strong> gene, which is necessary for the <strong>transfer of lipids to nascent chylomicrons in the small intestine and VLDL in the liver</strong>.</li>\n<li>This defect leads to the <strong>absence of chylomicrons, VLDL, LDL, and ApoB</strong>, and results in <strong>very low plasma cholesterol and triglyceride levels</strong>.</li>\n</ul>\n<p><strong>Clinical features</strong> include:</p>\n<ul>\n<li><strong>Fat malabsorption</strong>, chronic <strong>diarrhoea</strong>, and <strong>failure to thrive</strong> in early childhood</li>\n<li><strong>Acanthocytosis</strong> is seen on the peripheral smear</li>\n<li><strong>Pigmentary retinopathy</strong> causes progressive <strong>night and colour blindness</strong>, potentially leading to <strong>complete blindness</strong></li>\n<li><strong>Neurological manifestations</strong> (spinocerebellar degeneration) due to <strong>vitamin E deficiency</strong>, including <strong>loss of deep tendon reflexes</strong>, <strong>ataxia</strong>, and <strong>lower limb spasticity</strong> developing over time</li>\n</ul>\n<ul>\n<li>The <strong>neurologic symptoms and retinopathy</strong> may mimic <strong>Friedreich's ataxia</strong>, but the <strong>presence of fat malabsorption and acanthocytosis</strong> helps differentiate it.</li>\n<li>These clinical manifestations primarily result from <strong>malabsorption of fat-soluble vitamins</strong>, especially <strong>vitamins E, A, and K</strong>.</li>\n<li>Early and continuous <strong>vitamin E supplementation</strong> may <strong>significantly slow neurologic deterioration</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>MTP - Tangier's disease (Option A): </strong>MTP mutations cause <strong>abetalipoproteinemia</strong>, not Tangier&rsquo;s disease.</p>\n<p><strong>ABCA1 - Tangier's disease (Option B):</strong> ABCA1 mutation causes <strong>Tangier&rsquo;s disease</strong>, characterised by absent HDL but <strong>not</strong> low chylomicrons or VLDL.</p>\n<p><strong>ABCA1 - Abetalipoproteinemia (Option D):</strong> ABCA1 is not involved in chylomicron or VLDL metabolism; hence, this does not cause abetalipoproteinemia.</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1,b-2,c-3,d-4</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">a-4,b-3,c-1,d-2</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">a-4,b-3,c-2,d-1</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">a-1,b-3,c-2,d-4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the apoprotein with the lipoprotein:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090180bb361b-10ba-4c76-95d4-1ce232ab7288.png\"></span></p>",
      "unique_key": "DT1169954",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169954,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The apoproteins present in the lipoproteins are as follows:</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250901f8d1fc1e-adc6-4b0f-8b21-58b19b230028.png\">\n<ul>\n<li><strong>Apo B-48</strong> - specific to <strong>chylomicrons</strong></li>\n<li><strong>Apo B-100</strong> - found in <strong>VLDL</strong> and <strong>LDL</strong></li>\n<li><strong>Apo A and Apo E</strong> are prominent in <strong>HDL</strong></li>\n</ul>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Butyrate acid</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Palmitic acid</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Stearic acid</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Oleic acid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following is not a saturated fatty acid?</span></p>",
      "unique_key": "DT1169999",
      "question_audio": null,
      "question_video": null,
      "map_id": 1169999,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Saturated fatty acids</strong> are those that do not have a double bond.</li>\n<li>They include <strong>palmitate</strong>, <strong>stearic</strong>, <strong>butyric</strong>, acetic, caproic, and valeric acids, etc.</li>\n</ul>\n<p><strong>(Options A, B and C ruled out)</strong></p>\n<ul>\n<li><strong>Unsaturated</strong> fatty acids are those with the presence of <strong>double bonds</strong>. They can be divided into:\n<ul>\n<li><strong>Monounsaturated fats:</strong> contain one double bond. eg, <strong>oleic acid</strong></li>\n<li><strong>Polyunsaturated fats:</strong> those with more than one double bond. E.g., linoleic acid, arachidonic acid</li>\n</ul>\n</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509014a6a5f59-f463-452f-a3a1-ed1af80f1cef.png\">",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-B, 3-C, 4-D, 5-E, 6-F</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D, 2-E, 3-C, 4-F, 5-B, 6-A</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">1-F, 2-E, 3-C, 4-D, 5-A, 6-B</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">1-E, 2-D, 3-F, 4-C, 5-A, 6-B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the apolipoproteins with their respective function:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090159e3aa5a-0883-49b2-872e-fce9e6c19821.png\"></span></p>",
      "unique_key": "DT1170006",
      "question_audio": null,
      "question_video": null,
      "map_id": 1170006,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The correct matching is based on well-established roles of the apolipoproteins:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250901681d5007-8a6e-4a13-9692-36cfcba480f2.png\">",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Defect of beta oxidation</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Accumulation of Phytanic acid</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Peripheral neuropathy</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Treated by removing Phytanic acid precursors from the diet</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The following are the features of Refsum's disease except:</span></p>",
      "unique_key": "DT1191013",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191013,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Refsum's Disease</strong></p>\n<ul>\n<li><strong>Rare autosomal recessive disorder due to a defect in Alpha oxidation of Phytanic Acid</strong>(Phytanic Acid Oxidase) <strong>(phytanoyl CoA hydroxylase) </strong>in the Peroxisome. This leads to the <strong>accumulation of phytanic acid</strong>. <strong>(Option B)</strong></li>\n<li>The manifestation of classic Refsum's Disease includes impaired vision from <strong>retinitis pigmentosa, ichthyosis, peripheral neuropathy, ataxia, and, occasionally, cardiac</strong> <strong>arrhythmias</strong>. <strong>(Option C)</strong></li>\n<li>Classic Refsum disease often does not manifest until young adulthood, but <strong>visual disturbances such as night blindness, ichthyosis, and peripheral neuropathy may already be present in childhood and adolescence</strong>.</li>\n<li>Management involves <strong>dietary restriction of phytanic acid (</strong>dietary dairy products and Green Leafy Vegetables) <strong>(Option D)</strong></li>\n</ul>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetyl-CoA</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">H2O2 formed</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Different enzymes are found in different sites</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">NADH is required</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Fatty acid-oxidation (&beta;-oxidation) in peroxisomes is differentiated from that occurring in mitochondria by:</span></p>",
      "unique_key": "DT1191018",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191018,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer:</strong></p>\r\n<ul>\r\n<li><strong>Peroxisomes oxidise very long-chain fatty acids (VLCFAs)</strong> using a <strong>modified &beta;-oxidation pathway</strong>, which results in the formation of <strong>acetyl-CoA</strong> and <strong>hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)</strong>.</li>\r\n<li>The <strong>flavoprotein-linked dehydrogenase</strong> step in peroxisomal &beta;-oxidation produces <strong>H<sub>2</sub>O<sub>2</sub></strong>, which is then broken down by <strong>catalase</strong>.</li>\r\n<li>Unlike in mitochondria, <strong>peroxisomal oxidation is not coupled to ATP generation</strong>, as it is <strong>not linked to oxidative phosphorylation</strong>.</li>\r\n<li>This system is especially suited for <strong>very long chain fatty acids (e.g., C20, C22)</strong>.</li>\r\n<li><strong>&beta;-oxidation in peroxisomes</strong> ends at <strong>octanoyl-CoA</strong>, which, along with <strong>acetyl-CoA</strong>, is further oxidised in <strong>mitochondria</strong>.</li>\r\n<li>The enzymes involved are induced by <strong>high-fat diets</strong> and in some species by <strong>hypolipidemic drugs</strong> (e.g., <strong>clofibrate</strong>).</li>\r\n<li>Peroxisomes also function in <strong>bile acid formation</strong> (by shortening the side chain of cholesterol) and in <strong>ether glycerolipid synthesis</strong>.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Acetyl-CoA (Option A) </strong>is formed in both peroxisomal and mitochondrial &beta;-oxidation.</p>\r\n<p><strong>Different enzymes are found in different sites (Option C): </strong>While true in general, this is not the specific distinguishing biochemical feature.</p>\r\n<p><strong>NADH is required (Option D): </strong>Peroxisomal &beta;-oxidation does not couple with NADH or ATP production; instead, it forms H<sub>2</sub>O<sub>2</sub><strong>.</strong></p>",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetyl-CoA + Acetyl-CoA</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetyl-CoA + Propionyl CoA</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Propionyl CoA + Propionyl CoA</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetyl-CoA alone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is obtained as the end product in the &beta;-oxidation of odd-chain fatty acids?</span></p>",
      "unique_key": "DT1191025",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191025,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Oxidation of Odd-Chain Fatty Acids:</strong></p>\r\n<ul>\r\n<li>Takes place in the <strong>mitochondria</strong>.</li>\r\n<li>During &beta;-oxidation, <strong>fatty acids with an odd number of carbon atoms</strong> are broken down to yield:\r\n<ul>\r\n<li><strong>Multiple molecules of Acetyl-CoA</strong>, and</li>\r\n<li><strong>One molecule of Propionyl-CoA</strong> at the end. <strong>(Option C ruled out)</strong></li>\r\n</ul>\r\n</li>\r\n<li>The final three-carbon fragment is released as <strong>Propionyl-CoA</strong>.</li>\r\n<li>This <strong>Propionyl-CoA</strong> is metabolised to <strong>Succinyl-CoA</strong>, which enters the <strong>TCA cycle</strong>.</li>\r\n<li>Hence, <strong>Propionyl-CoA</strong> is <strong>glucogenic</strong>, making it the <strong>only glucogenic portion</strong> of a fatty acid.</li>\r\n<li>Even-chain fatty acids yield only <strong>Acetyl-CoA</strong>, which is <strong>ketogenic</strong>. <strong>(Options A and D ruled out)</strong></li>\r\n<li><strong>Odd-chain fatty acids</strong> are unique in providing a <strong>glucogenic</strong> component (Propionyl CoA).</li>\r\n</ul>\r\n<p>Propionyl CoA &rarr; Methylmalonyl CoA &rarr; Succinyl CoA (via vitamin B12-dependent enzyme)</p>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">HMG CoA reductase</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">HMG CoA lyase</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Mitochondrial HMG CoA synthase</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiolase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the common enzyme shared between cholesterol synthesis and ketone body synthesis?</span></p>",
      "unique_key": "DT1191033",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191033,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Thiolase</strong> is an enzyme involved in <strong>ketone body synthesis</strong>. Thiolase converts <strong>acetoacetyl-CoA to acetyl-CoA.</strong></li>\n<li>In <strong>Cholesterol synthesis</strong>, two molecules of <strong>acetyl-CoA condense to form acetoacetyl-CoA by Thiolase.</strong></li>\n<li>Site of synthesis differs: <strong>mitochondria</strong> for ketone bodies, <strong>cytoplasm</strong> for cholesterol.</li>\n<li><strong>Cytoplasmic HMG CoA</strong> Synthase is for Cholesterol synthesis.</li>\n<li><strong>Mitochondrial HMG CoA</strong> Synthase is for ketone body synthesis. <strong>(Option C ruled out)</strong></li>\n<li><strong>HMG CoA reductase</strong>: specific to cholesterol synthesis, not common. <strong>(Option A ruled out)</strong></li>\n<li><strong>HMG CoA lyase</strong>: specific to ketone body synthesis. <strong>(Option B ruled out)</strong></li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509011d3b8b66-5f2f-46d6-8676-7b605aae814f.png\">",
      "correct_choice_id": 184,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Bile salt</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Bile pigment</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Steroid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All are derived from cholesterol except:</span></p>",
      "unique_key": "DT1191036",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191036,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Bile pigment</strong> is <strong>not</strong> derived from cholesterol, unlike vitamin D, bile salts, and steroids. Bile pigments like <strong>bilirubin</strong> originate from the <strong>breakdown of heme</strong> (from haemoglobin), not from cholesterol metabolism.</li>\n<li>Cholesterol acts as the <strong>precursor</strong> for several important biomolecules, such as:\n<ul>\n<li><strong>Bile acids/salts (Option B)</strong></li>\n<li><strong>Steroid hormones</strong> (e.g., cortisol, testosterone, estrogen) <strong>(Option D)</strong></li>\n<li><strong>Vitamin D (Option A)</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>Bile pigments are products of <strong>heme catabolism</strong>, not cholesterol metabolism.</li>\n<li>Cholesterol serves as a vital precursor for multiple hormone and vitamin pathways.</li>\n</ul>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">FADH2</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">FMNH2</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">NADPH</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">NADH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which coenzyme acts as a reducing agent in the anabolic reaction of cholesterol?</span></p>",
      "unique_key": "DT1191037",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191037,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li><strong>NADPH</strong> specifically serves as the reducing agent in anabolic reactions like <strong>cholesterol synthesis</strong>, <strong>fatty acid synthesis</strong>, and <strong>steroid hormone biosynthesis</strong>, whereas other coenzymes listed do not participate in these reductive biosynthetic pathways.</li>\r\n<li>NADPH donates <strong>high-energy electrons (hydride ions)</strong> in <strong>biosynthetic (anabolic)</strong></li>\r\n</ul>\r\n<p><strong>Functions of NADPH include:</strong></p>\r\n<ol>\r\n<li><strong>Synthesis of fatty acids</strong></li>\r\n<li><strong>Synthesis of cholesterol and steroids</strong></li>\r\n<li><strong>Synthesis of glutamate</strong> from &alpha;-ketoglutarate</li>\r\n<li><strong>Synthesis of tyrosine</strong> from phenylalanine</li>\r\n<li><strong>Uronic acid pathway</strong> (synthesis of glucuronic acid)</li>\r\n<li><strong>Folate metabolism</strong> (tetrahydrofolate regeneration)</li>\r\n<li><strong>Antioxidant defence</strong> - by reducing oxidised glutathione to its active reduced form</li>\r\n</ol>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>FADH<sub>2</sub></strong> <strong>(Option A):</strong> Acts in <strong>oxidative</strong> pathways like the electron transport chain; not a reducing agent in biosynthesis.</p>\r\n<p><strong>FMNH<sub>2</sub></strong> <strong>(Option B): </strong>Functions as a prosthetic group in <strong>flavoproteins</strong> in electron transport, not in anabolic processes.</p>\r\n<p><strong>NADH (Option D):</strong> Used in <strong>catabolic</strong> processes and energy generation, not in reductive biosynthesis.</p>\r\n<h3><strong>Key Takeaways:</strong></h3>\r\n<ul>\r\n<li><strong>NADPH = Reductive biosynthesis</strong></li>\r\n<li><strong>NADH/FADH<sub>2</sub> = Energy production (oxidation)</strong></li>\r\n<li>Anabolism = NADPH dependent</li>\r\n<li>Catabolism = NADH/FADH<sub>2</sub> dependent</li>\r\n</ul>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetyl-CoA</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Malonyl CoA</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Aceto acetate</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">NADPH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following compounds is the source of all carbon atoms in cholesterol synthesis?</span></p>",
      "unique_key": "DT1191041",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191041,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Acetyl-CoA is the <strong>exclusive source of all 27 carbon atoms</strong> in the cholesterol molecule, unlike malonyl-CoA, acetoacetate, or NADPH, which do not contribute carbon atoms to the cholesterol skeleton.</li>\n<li>Cholesterol is synthesised in a <strong>multi-step anabolic pathway</strong> beginning with <strong>acetyl-CoA</strong>.</li>\n<li>The pathway involves:\n<ul>\n<li><strong>Synthesis of mevalonate</strong> from acetyl-CoA</li>\n<li><strong>Formation of isoprenoid units</strong> via loss of CO<sub>2</sub></li>\n<li><strong>Condensation of 6 isoprenoid units</strong> to form <strong>squalene</strong></li>\n<li><strong>Cyclisation of squalene</strong> into <strong>lanosterol</strong></li>\n<li><strong>Conversion of lanosterol</strong> to <strong>cholesterol</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Malonyl CoA (Option B): </strong>Used in fatty acid synthesis, not cholesterol biosynthesis.</p>\n<p><strong>Acetoacetate (Option C): </strong>A ketone body derived from acetyl-CoA, but not a direct carbon donor in cholesterol synthesis.</p>\n<p><strong>NADPH (Option D): </strong>NADPH is used as a reducing agent, not a carbon donor, in the process.</p>",
      "correct_choice_id": 211,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Glycocholic acid</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholic acid</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Chenodeoxycholic acid</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Deoxycholic acid</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following are primary bile acids except:</span></p>",
      "unique_key": "DT1191049",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191049,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Deoxycholic acid</strong> is a <strong>secondary bile acid</strong> formed in the intestine by bacterial dehydroxylation of primary bile acids.</li>\n<li>In contrast, cholic acid and chenodeoxycholic acid are synthesised in the liver and are true primary bile acids. Glycocholic acid is a conjugate of cholic acid with glycine and thus also considered primary.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509019704331f-3c64-4d09-bad8-ff5d98ea2a2a.png\">",
      "correct_choice_id": 224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholesterol</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid hormone</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucagon</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucocorticoids.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Cholesterol synthesis is controlled by the regulation of the HMG CoA reductase enzyme. All of the following factors inhibit the activity of HMG CoA reductase, except:</span></p>",
      "unique_key": "DT1191052",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191052,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer</strong>:</p>\n<ul>\n<li><strong>Thyroid hormone</strong> <strong>stimulates</strong> the activity of HMG CoA reductase and therefore increases cholesterol synthesis, unlike the other options, which inhibit the enzyme.</li>\n<li><strong>HMG-CoA reductase</strong> is the <strong>rate-limiting enzyme</strong> in cholesterol biosynthesis.</li>\n<li>Regulation of this enzyme occurs via <strong>hormonal, feedback, and phosphorylation/dephosphorylation mechanisms.</strong></li>\n</ul>\n<h3><strong>Explanation of other options</strong><strong>:</strong></h3>\n<p><strong>Cholesterol</strong> <strong>(Option A):</strong> Acts as a feedback inhibitor of HMG-CoA reductase. When intracellular cholesterol levels are high, enzyme activity is suppressed.</p>\n<p><strong>Glucagon</strong> <strong>(Option C):</strong> Inhibits HMG-CoA reductase by promoting its <strong>phosphorylation</strong>, thereby reducing cholesterol synthesis during fasting or low-energy states.</p>\n<p><strong>Glucocorticoids</strong> <strong>(Option D):</strong> These inhibit the transcription of genes involved in cholesterol biosynthesis, including HMG-CoA reductase.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Stimulators</strong> of HMG CoA reductase: Insulin, Thyroid hormone</li>\n<li><strong>Inhibitors</strong>: Glucagon, Cholesterol, Mevalonate, Glucocorticoids</li>\n</ul>\n<p>Regulation occurs at both <strong>transcriptional</strong> and <strong>post-translational</strong> levels</p>",
      "correct_choice_id": 232,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">apo E</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">apo A and apo E</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">apo E and apo B100</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">apo B100</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is the ligand for the receptors present in the liver for the uptake of LDL?</span></p>",
      "unique_key": "DT1191053",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191053,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Apo B100 is the specific ligand that binds the LDL receptor for the hepatic uptake of LDL particles.</strong></li>\n<li><strong>Apo E</strong> mediates the uptake of remnant lipoproteins (e.g., chylomicron remnants and VLDL remnants). <strong>(Option A ruled out)</strong></li>\n<li>The <strong>LDL receptor</strong> has binding sites for both <strong>apo B100</strong> and <strong>apo E</strong>.</li>\n<li><strong>Ligand Specificity:</strong></li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090189c8694b-1839-441f-aedc-7cea8b0a41a6.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Apo A and apo E (Option B): Apo A</strong> is associated with HDL and plays no role in LDL receptor binding; apo E is for remnants only.</p>\n<p><strong>Apo E and apo B100 (Option C): </strong>While both bind LDL receptors, only <strong>apo B100</strong> is involved in LDL uptake, making this option inaccurate for this specific context.</p>",
      "correct_choice_id": 244,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver cirrhosis</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">Atherosclerosis</span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephritic syndrome</span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Pancreatitis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Increased level of lipoprotein (a) predisposes to:</span></p>",
      "unique_key": "DT1191057",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191057,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Lipoprotein (a) </strong>is structurally similar to<strong> LDL </strong>and is strongly associated with<strong> atherosclerosis and myocardial infarction </strong>due to its<strong> interference with fibrinolysis.</strong></li>\n<li>Lipoprotein (a) consists of an LDL-like particle linked to <strong>apo B100</strong> by a disulfide bond and is rich in cholesterol.</li>\n<li>It has <strong>structural similarity to plasminogen</strong>, which allows it to compete with plasminogen for binding sites but <strong>does not promote fibrinolysis</strong>.</li>\n<li>This competition <strong>inhibits the conversion of plasminogen to plasmin</strong>, thereby <strong>preventing fibrin clot lysis</strong>, contributing to a <strong>prothrombotic state</strong>.</li>\n<li>Elevated levels are an independent risk factor for <strong>atherosclerotic cardiovascular diseases (ASCVD)</strong> and <strong>coronary artery disease</strong>.</li>\n</ul>\n<p><strong>Lipoprotein x:</strong></p>\n<ul>\n<li>Cholesterol is excreted as bile acids in the bile.</li>\n<li>In cholestasis, cholesterol combines with Phospholipid and forms <strong>Lipoprotein X.</strong></li>\n<li>Hence, it is an <strong>index of cholestasis.</strong></li>\n</ul>\n<p><strong>Explanation of other options</strong>:</p>\n<p><strong>Liver cirrhosis (Option A):</strong> Not associated with Lp(a). Liver diseases may affect various lipoproteins, but Lp(a) elevation is not a marker or cause.</p>\n<p><strong>Nephritic syndrome (Option C):</strong> While nephrotic syndrome causes lipid abnormalities, <strong>Lp(a)</strong> is not typically implicated in <strong>nephritic</strong> syndrome.</p>\n<p><strong>Pancreatitis (Option D):</strong> Pancreatitis is commonly associated with elevated <strong>triglycerides</strong>, especially chylomicrons and VLDL, not Lp(a).</p>",
      "correct_choice_id": 252,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 27,
      "choices": [
        {
          "id": 261,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicrons</span></p>"
        },
        {
          "id": 262,
          "text": "<p><span style=\"font-size:12.0pt;\">VLDL</span></p>"
        },
        {
          "id": 263,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL</span></p>"
        },
        {
          "id": 264,
          "text": "<p><span style=\"font-size:12.0pt;\">HDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In which of the lipoprotein compounds is, triglyceride component maximum?</span></p>",
      "unique_key": "DT1191060",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191060,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Chylomicrons</strong> are the largest and least dense lipoproteins.</li>\n<li>They are synthesised in the <strong>intestinal mucosa</strong> and are responsible for transporting <strong>dietary triglycerides</strong> from the intestine to peripheral tissues.</li>\n<li>Their composition is <strong>90-98% lipid</strong>, of which <strong>80-90% is triglyceride</strong>, making them the lipoprotein with the <strong>highest triglyceride content</strong>.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090149b3fa76-5c91-45bd-b5f5-78eef41c6542.png\">",
      "correct_choice_id": 261,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 28,
      "choices": [
        {
          "id": 271,
          "text": "<p><span style=\"font-size:12.0pt;\">Chylomicron</span></p>"
        },
        {
          "id": 272,
          "text": "<p><span style=\"font-size:12.0pt;\">VLDL</span></p>"
        },
        {
          "id": 273,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL</span></p>"
        },
        {
          "id": 274,
          "text": "<p><span style=\"font-size:12.0pt;\">HDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Cholesterol from dietary sources is transported to the peripheral tissue by:</span></p>",
      "unique_key": "DT1191070",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p><strong>Transport of cholesterol</strong> between tissues</p>\n<ul>\n<li>Dietary cholesterol is <strong>incorporated into chylomicrons.</strong></li>\n<li>95% of chylomicron cholesterol is delivered to the liver in the <strong>Chylomicron remnant</strong>.</li>\n<li>The <strong>cholesterol is secreted from the liver in VLDL.</strong></li>\n<li>Most of the cholesterol secreted in VLDL is retained in IDL and <strong>ultimately LDL.</strong></li>\n<li><strong>LDL cholesterol is taken up by the liver and extrahepatic tissues (peripheral tissues).</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Chylomicron (Option A): </strong>Transports <strong>dietary triglycerides</strong> from the intestine to peripheral tissues. The majority of chylomicron cholesterol is returned to the liver, not to peripheral tissues.</p>\n<p><strong>VLDL (Option B): </strong>Transports <strong>endogenously synthesised triglycerides</strong> from the liver to peripheral tissues. Its cholesterol is mostly retained and delivered through LDL after sequential processing.</p>\n<p><strong>HDL (Option D): </strong>Functions primarily in <strong>reverse cholesterol transport</strong> (from peripheral tissues to liver). Not responsible for delivering dietary cholesterol to peripheral tissues.</p>",
      "correct_choice_id": 273,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 29,
      "choices": [
        {
          "id": 281,
          "text": "<p><span style=\"font-size:12.0pt;\">To form remnant lipoprotein</span></p>"
        },
        {
          "id": 282,
          "text": "<p><span style=\"font-size:12.0pt;\">Promote Lipolysis in Adipose Tissue</span></p>"
        },
        {
          "id": 283,
          "text": "<p><span style=\"font-size:12.0pt;\">To form mature Chylomicron</span></p>"
        },
        {
          "id": 284,
          "text": "<p><span style=\"font-size:12.0pt;\">To form HDL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following is the action of lipoprotein lipase?</span></p>",
      "unique_key": "DT1191072",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Lipoprotein lipase (LPL)</strong> is an extracellular enzyme anchored to capillary endothelium, especially in <strong>adipose tissue, skeletal muscle, and heart</strong>.</li>\n<li>It hydrolyses <strong>triacylglycerols (TAGs)</strong> from circulating <strong>chylomicrons and VLDL</strong> into <strong>free fatty acids</strong> and <strong>glycerol</strong>.</li>\n<li>It forms <strong>remnant particles,</strong> which are cleared by the liver.</li>\n<li>This enzymatic action removes <strong>70&ndash;90% of the TAG content</strong>, converting:\n<ul>\n<li><strong>Chylomicrons &rarr; Chylomicron remnants</strong></li>\n<li><strong>VLDL &rarr; VLDL remnants (IDL)</strong></li>\n</ul>\n</li>\n<li><strong>Apo C</strong> is transferred to HDL during this reaction, while <strong>Apo E</strong> is retained on remnant particles to aid in hepatic clearance.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Promote lipolysis in adipose tissue (Option B): </strong>Lipolysis in adipose tissue is carried out by <strong>hormone-sensitive lipase</strong>, not lipoprotein lipase.</p>\n<p><strong>To form mature chylomicron (Option C): </strong>Maturation of chylomicrons occurs in plasma by acquiring <strong>apolipoproteins C-II and E</strong> from HDL; LPL is not involved.</p>\n<p><strong>To form HDL (Option C): </strong>HDL formation involves secretion by the <strong>liver and intestine</strong>, and subsequent lipid acquisition, not mediated by LPL.</p>",
      "correct_choice_id": 281,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 30,
      "choices": [
        {
          "id": 291,
          "text": "<p><span style=\"font-size:12.0pt;\">Represents primarily cholesterol that is being removed from peripheral cells.</span></p>"
        },
        {
          "id": 292,
          "text": "<p><span style=\"font-size:12.0pt;\">Binds to a receptor, and cholesterol diffuses across the cell membrane.</span></p>"
        },
        {
          "id": 293,
          "text": "<p><span style=\"font-size:12.0pt;\">Accumulation in the cell inhibits replenishment of LDL receptors.</span></p>"
        },
        {
          "id": 294,
          "text": "<p><span style=\"font-size:12.0pt;\">When it enters a cell, it suppresses the activity of acyl-CoA: cholesterol acyltransferase ACAT</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is true regarding cholesterol present in LDL?</span></p>",
      "unique_key": "DT1191079",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191079,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>LDL</strong> transports <strong>cholesterol esters</strong> derived from VLDL metabolism to <strong>peripheral tissues</strong>. <strong>(Option A ruled out)</strong></li>\n<li>LDL binds to the <strong>LDL receptor</strong> via its <strong>apo B-100</strong></li>\n<li>The complex is internalised by <strong>receptor-mediated endocytosis</strong> via <strong>clathrin-coated pits</strong>. <strong>(Option B ruled out)</strong></li>\n<li>In the <strong>lysosome</strong>, LDL is degraded, and <strong>free cholesterol</strong> is released into the cell.</li>\n</ul>\n<h4><strong>Cellular Effects of Increased Intracellular Cholesterol:</strong></h4>\n<ul>\n<li><strong>Decreases de novo cholesterol synthesis</strong> (inhibits <strong>HMG-CoA reductase</strong> via SREBP pathway)</li>\n<li><strong>Decreases LDL receptor synthesis (prevents further uptake of LDL)</strong></li>\n<li><strong>Increases activity of ACAT</strong> (acyl-CoA cholesterol acyltransferase), which esterifies free cholesterol for storage. <strong>(Option D ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 293,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31,
      "choices": [
        {
          "id": 301,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial type III hyperlipoproteinemia</span></p>"
        },
        {
          "id": 302,
          "text": "<p><span style=\"font-size:12.0pt;\">Abetalipoproteinemia</span></p>"
        },
        {
          "id": 303,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial LPL deficiency (type1)</span></p>"
        },
        {
          "id": 304,
          "text": "<p><span style=\"font-size:12.0pt;\">LDL receptor mutation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient was diagnosed with an isolated increase in LDL. His father and brother had the same disease with increased cholesterol. What is the likely diagnosis?</span></p>",
      "unique_key": "DT1191082",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191082,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Familial hypercholesterolemia</strong> is caused by a <strong>mutation in the LDL receptor gene</strong>, leading to <strong>defective or absent LDL receptors</strong>.</li>\n<li>This results in <strong>impaired clearance of LDL particles</strong>, causing an <strong>isolated increase in LDL cholesterol</strong> in plasma.</li>\n<li>The condition shows <strong>autosomal dominant inheritance</strong>, often with a family history (as seen in the father and brother).</li>\n<li>Patients are at high risk of <strong>premature atherosclerosis and coronary artery disease</strong>.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250901458a1368-7e6f-4a99-96f2-9f7f76d67342.png\">",
      "correct_choice_id": 304,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 32,
      "choices": [
        {
          "id": 311,
          "text": "<p><span style=\"font-size:12.0pt;\">Deficient LDL receptors</span></p>"
        },
        {
          "id": 312,
          "text": "<p><span style=\"font-size:12.0pt;\">Deficient HDL receptors</span></p>"
        },
        {
          "id": 313,
          "text": "<p><span style=\"font-size:12.0pt;\">HMG CoA reductase deficiency</span></p>"
        },
        {
          "id": 314,
          "text": "<p><span style=\"font-size:12.0pt;\">Deficient VLDL receptors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Familial hypercholesterolemia is:</span></p>",
      "unique_key": "DT1191085",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191085,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p>Disease: Familial hypercholesterolemia (type IIa)</p>\n<p>Defect: Defective LDL receptors or a mutation in the ligand region of apo B-100.</p>\n<p>Remarks: Elevated LDL levels and hypercholesterolemia, resulting in atherosclerosis and coronary disease.</p>",
      "correct_choice_id": 311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33,
      "choices": [
        {
          "id": 321,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo B100</span></p>"
        },
        {
          "id": 322,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo B48</span></p>"
        },
        {
          "id": 323,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo E</span></p>"
        },
        {
          "id": 324,
          "text": "<p><span style=\"font-size:12.0pt;\">Apo CII</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Absence of this apo lipoprotein is responsible for the genetic disorder, familial type III hyperlipoproteinemia:</span></p>",
      "unique_key": "DT1191090",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191090,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Familial type III hyperlipoproteinemia</strong> (also known as broad beta disease, remnant removal disease, or familial dysbetalipoproteinemia) is caused by an abnormality in <strong>Apolipoprotein E (Apo E)</strong>.</li>\n<li>The defect lies in the <strong>remnant clearance</strong> by the liver. Normally, Apo E binds to <strong>hepatic receptors</strong> and mediates the uptake of <strong>chylomicron remnants and VLDL remnants</strong>.</li>\n<li>In affected individuals, both <strong>Apo E3 and Apo E4 isoforms are absent</strong>, and only <strong>Apo E2</strong> is present, which <strong>does not bind effectively</strong> to hepatic Apo E receptors.</li>\n<li>This leads to the <strong>accumulation of remnant lipoproteins</strong>, especially &beta;-VLDL (density &lt;1.019), and results in <strong>hypercholesterolemia</strong>, <strong>xanthomas</strong>, and <strong>increased atherosclerotic risk.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Apo B100 (Option A): </strong>This is a structural protein found in <strong>VLDL, IDL, and LDL</strong> and is responsible for binding to <strong>LDL receptors</strong>. It is not involved in remnant clearance and is not the cause of type III hyperlipoproteinemia.</p>\n<p><strong>Apo B48 (Option B): </strong>Found in <strong>chylomicrons and chylomicron remnants</strong>. Involved in intestinal lipid transport, but does not mediate remnant clearance via the liver.</p>\n<p><strong>Apo CII (Option D): </strong>Activates <strong>lipoprotein lipase (LPL)</strong>, which hydrolyses triglycerides in chylomicrons and VLDL. Its deficiency causes <strong>type I hyperlipoproteinemia</strong>, not type III.</p>",
      "correct_choice_id": 323,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 34,
      "choices": [
        {
          "id": 331,
          "text": "<p><span style=\"font-size:12.0pt;\">It decreases the number of LDL receptors exposed at the cell surface, thus LDL uptake is lowered, and blood cholesterol levels rise.</span></p>"
        },
        {
          "id": 332,
          "text": "<p><span style=\"font-size:12.0pt;\">It inhibits the binding of apoB to the LDL receptor, thus blocking uptake of the lipoprotein and raising blood cholesterol levels.</span></p>"
        },
        {
          "id": 333,
          "text": "<p><span style=\"font-size:12.0pt;\">It prevents the breakdown of cholesterol to bile acids in the liver.</span></p>"
        },
        {
          "id": 334,
          "text": "<p><span style=\"font-size:12.0pt;\">It increases the synthesis and secretion of VLDL in the liver, leading to increased LDL formation in the blood.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The recently discovered protein, proprotein convertase subtilisin/kexin type 9 (PCSK9), has been identified as a potential target for antiatherogenic drugs because:</span></p>",
      "unique_key": "DT1191098",
      "question_audio": null,
      "question_video": null,
      "map_id": 1191098,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)</strong> plays a regulatory role in cholesterol homeostasis by targeting <strong>LDL receptors (LDLR)</strong> for degradation.</li>\n<li>After <strong>LDL receptor-mediated endocytosis</strong>, LDL receptors are typically recycled back to the hepatocyte surface to continue LDL clearance.</li>\n<li>However, <strong>PCSK9 binds to LDL receptors and targets them for lysosomal degradation</strong>, thus <strong>reducing the number of receptors available at the cell surface</strong>.</li>\n<li>This leads to <strong>decreased LDL clearance from the plasma</strong>, causing an <strong>increase in blood LDL cholesterol levels</strong>.</li>\n<li>Therefore, <strong>inhibition of PCSK9</strong> (by monoclonal antibodies or siRNA-based drugs) is a <strong>therapeutic strategy to increase LDL receptor expression</strong>, thereby lowering LDL-C levels.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>It inhibits the binding of apoB to the LDL receptor, thus blocking uptake of the lipoprotein and raising blood cholesterol levels (Option B):</strong> PCSK9 does not inhibit ApoB binding to the LDL receptor. LDL particles are internalised through ApoB100 interaction with LDLR.</p>\n<p><strong>It prevents the breakdown of cholesterol to bile acids in the liver (Option C): </strong>Bile acid synthesis is regulated by enzymes like <strong>CYP7A1</strong>, not PCSK9. PCSK9 has no direct role in cholesterol catabolism to bile acids.</p>\n<p><strong>It increases the synthesis and secretion of VLDL in the liver, leading to increased LDL formation in the blood (Option D):</strong> VLDL synthesis is governed by lipid availability and transcription factors like <strong>SREBP-1c</strong>, not PCSK9.</p>",
      "correct_choice_id": 331,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35,
      "choices": [
        {
          "id": 341,
          "text": "<p><span style=\"font-size:12.0pt;\">Easily recognised by the liver LDL receptor</span></p>"
        },
        {
          "id": 342,
          "text": "<p><span style=\"font-size:12.0pt;\">Easily cleared by the liver</span></p>"
        },
        {
          "id": 343,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases risk of atherosclerosis</span></p>"
        },
        {
          "id": 344,
          "text": "<p><span style=\"font-size:12.0pt;\">Not taken up by macrophage scavenger receptors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following sentences is true regarding chemical modification of LDL (low-density lipoprotein) by free radicals?</span></p>",
      "unique_key": "DT1192285",
      "question_audio": null,
      "question_video": null,
      "map_id": 1192285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Free radical&ndash;induced modification of LDL leads to <strong>oxidised LDL (oxLDL)</strong>, which is <strong>not recognised by LDL receptors on hepatocytes</strong> and is <strong>not cleared via the regular LDL pathway</strong>. <strong>(Option A and B ruled out)</strong></li>\n<li>Instead, it is taken up by <strong>macrophage scavenger receptors</strong>, particularly SR-A, which are not downregulated. <strong>(Option D ruled out)</strong></li>\n<li>This results in unregulated uptake of oxLDL, forming <strong>foam cells</strong>, which accumulate in the intima of blood vessels and initiate <strong>atherosclerotic plaque formation</strong>.</li>\n<li>Therefore, oxidised LDL is <strong>highly atherogenic</strong>, directly linking to cardiovascular disease risk.</li>\n</ul>",
      "correct_choice_id": 343,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}